

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>CRESO PHARMA LIMITED</b>
<b>ABN</b>	<b>89 609 406 911</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Adam Blumenthal
<b>Date of last notice</b>	15 July 2021

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct & Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Atlantic Capital Holdings Pty <Atlantic Capital A/C> - a director-related entity.
<b>Date of change</b>	2 November 2021
<b>No. of securities held prior to change</b>	<b>Direct:</b> <b>Adam Blumenthal:</b> 1 Fully Paid Ordinary Share  <b>Indirect:</b> <b>Atlantic Capital Holdings Pty &lt;Atlantic Capital A/C&gt;:</b> 113,665,432 Fully Paid Ordinary Shares 2,128,387 CPHOPT20 Options (\$0.35, 12 Feb 2023) 4,000,000 CPHOPT29 Options (\$0.25, 2 Jun 2023) 8,000,000 CPHOPT31 Options (\$0.20, 2 Jun 2023) 12,000,000 CPHOPT38 Options (\$0.38, 14 Jul 2024)
<b>Class</b>	CPHO Listed Options (\$0.25, 2 Nov 2024)
<b>Number acquired</b>	37,888,479 CPHO Listed Options (\$0.25, 2 Nov 2024)
<b>Number disposed</b>	Nil.

+ See chapter 19 for defined terms.

## Appendix 3Y Change of Director's Interest Notice

<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Nil cash. Refer to the Bonus Options Prospectus released to ASX on 26 October 2021 for further information.
<b>No. of securities held after change</b>	<b>Direct:</b> <b>Adam Blumenthal:</b> 1 Fully Paid Ordinary Share 1 CPHO Listed Options (\$0.25, 2 Nov 2024)  <b>Indirect:</b> <b>Atlantic Capital Holdings Pty &lt;Atlantic Capital A/C&gt;:</b> 113,665,432 Fully Paid Ordinary Shares 37,888,478 CPHO Options (\$0.25, 2 Nov 2024) 2,128,387 CPHOPT20 Options (\$0.35, 12 Feb 2023) 4,000,000 CPHOPT29 Options (\$0.25, 2 Jun 2023) 8,000,000 CPHOPT31 Options (\$0.20, 2 Jun 2023)
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	The Options the subject of this Appendix 3Y were issued pursuant to the Bonus Options Prospectus released on the ASX on 26 October 2021.

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

+ See chapter 19 for defined terms.

**Part 3 - <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>CRESO PHARMA LIMITED</b>
<b>ABN</b>	<b>89 609 406 911</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Boaz Wachtel
<b>Date of last notice</b>	15 July 2021

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	International Water and Energy Savers Ltd (an entity controlled by Mr Wachtel)
<b>Date of change</b>	2 November 2021
<b>No. of securities held prior to change</b>	<u>Indirect:</u> <b>International Water and Energy Savers Ltd:</b> 8,800,000 Fully Paid Ordinary Shares 800,000 CPHPERR6 Performance Rights 800,000 CPHPERR7 Performance Rights
<b>Class</b>	CPHO Options (\$0.25, 2 Nov 2024)
<b>Number acquired</b>	2,933,334
<b>Number disposed</b>	Nil.
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Nil cash. Refer to the Bonus Options Prospectus released on the ASX on 26 October 2021 for further information.

+ See chapter 19 for defined terms.

## Appendix 3Y Change of Director's Interest Notice

<b>No. of securities held after change</b>	<b>Indirect:</b> <b>International Water and Energy Savers Ltd:</b> 8,800,000 Fully Paid Ordinary Shares 2,933,334 CPHO Options (\$0.25, 2 Nov 2024) 800,000 CPHPERR6 Performance Rights 800,000 CPHPERR7 Performance Rights
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	The Options the subject of this Appendix 3Y were issued pursuant to the Bonus Options Prospectus released on the ASX on 26 October 2021.

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

### Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>CRESO PHARMA LIMITED</b>
<b>ABN</b>	<b>89 609 406 911</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	James Ellingford
<b>Date of last notice</b>	15 July 2021

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
<b>Date of change</b>	2 November 2021
<b>No. of securities held prior to change</b>	1,152,500 Fully Paid Ordinary Shares
<b>Class</b>	CPHO Options (\$0.25, 2 Nov 2024)
<b>Number acquired</b>	384,167
<b>Number disposed</b>	Nil.
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Nil cash. Refer to the Bonus Options Prospectus released to ASX on 26 October 2021 for further information.
<b>No. of securities held after change</b>	1,152,500 Fully Paid Ordinary Shares  384,167 CPHO Options (\$0.25, 2 Nov 2024)
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	The Options the subject of this Appendix 3Y were issued pursuant to the Bonus Options Prospectus released on the ASX on 26 October 2021.

+ See chapter 19 for defined terms.

## Appendix 3Y Change of Director's Interest Notice

---

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
<b>Interest after change</b>	N/A

### Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.